Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
217.32
+2.27 (1.06%)
At close: Jan 14, 2026, 4:00 PM EST
213.10
-4.22 (-1.94%)
After-hours: Jan 14, 2026, 4:52 PM EST
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 16 analysts that cover Ascendis Pharma stock have a consensus rating of "Strong Buy" and an average price target of $262.38, which forecasts a 20.73% increase in the stock price over the next year. The lowest target is $220 and the highest is $325.
Price Target: $262.38 (+20.73%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ascendis Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 6 | 6 | 7 |
| Buy | 10 | 10 | 10 | 9 | 9 | 9 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 17 | 15 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $297 → $322 | Buy | Maintains | $297 → $322 | +48.17% | Jan 9, 2026 |
| TD Cowen | TD Cowen | Strong Buy Reiterates $325 | Strong Buy | Reiterates | $325 | +49.55% | Jan 7, 2026 |
| Stifel | Stifel | Strong Buy Maintains $254 → $256 | Strong Buy | Maintains | $254 → $256 | +17.80% | Dec 11, 2025 |
| Wedbush | Wedbush | Buy Reiterates $220 | Buy | Reiterates | $220 | +1.23% | Nov 18, 2025 |
| Raymond James | Raymond James | Strong Buy Initiates $271 | Strong Buy | Initiates | $271 | +24.70% | Oct 17, 2025 |
Financial Forecast
Revenue This Year
725.60M
from 363.64M
Increased by 99.54%
Revenue Next Year
1.34B
from 725.60M
Increased by 84.40%
EPS This Year
-3.25
from -6.53
EPS Next Year
3.25
from -3.25
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 764.9M | 1.6B | ||||
| Avg | 725.6M | 1.3B | ||||
| Low | 658.4M | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 110.4% | 119.5% | ||||
| Avg | 99.5% | 84.4% | ||||
| Low | 81.0% | 51.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.95 | 6.38 | ||||
| Avg | -3.25 | 3.25 | ||||
| Low | -3.69 | -0.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.